课题基金 / 基金详情

The roles of EZH2 and FOXO1A in CNS-PNET pathogenesis.

The roles of EZH2 and FOXO1A in CNS-PNET pathogenesis.
EZH2 和 FOXO1A 在 CNS-PNET 发病机制中的作用。
批准号:
nhmrc : 403983
负责人:
Dr Peter Dallas
金额:
$31.17万
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2006
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2006-01-01 至 2008-12-31
关键词:

项目摘要

项目成果

Dr Peter Dallas的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Although CNS-PNETs are the most common embryonal CNS tumours of childhood and cause significant mortality and morbidity, there is a very limited understanding of the pathogenesis of this aggressive disease. This situation is a major handicap to the development of more specific and effective therapies. While a better understanding of the fundamental pathology of CNS-PNETs will have immediate diagnostic implications, the elucidation of the biochemical pathways that are disrupted in these tumours will facilitate the design of new drugs that are specifically directed towards the critical proteins in these pathways. The identification of specific genes and-or pathways that are deregulated in CNS-PNET cells is essential for the development of safer, more directed, and more effective therapies that are urgently required for the treatment of those with this devastating disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tumour suppressor genes in PNET pathogenesis
  • 批准号:
    nhmrc : 254596
  • 项目类别:
    NHMRC Project Grants
  • 资助金额:
    $28.36万
  • 财政年份:
    2003
  • 负责人:
    Dr Peter Dallas
  • 依托单位:
国内基金
海外基金
基于多组学与可视化免疫动态成像技术解析EZH2抑制对增强CAR-NK细胞抗AML效应的机制研究
  • 批准号:
    JCZRLH202600775
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
RAD54L调控EZH2在肾透明细胞癌中的作用及机制研究
  • 批准号:
    JCZRLH202600988
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
基于EZH2甲基化靶向人肺腺癌干细胞“干性”的肺癌治疗新策略及其机制
  • 批准号:
    JCZRLH202601089
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
Ezh2通过STAT3/PD-1轴调控小胶质细胞极化介导脓毒症脑病的机制研究
  • 批准号:
    2026JJ80009
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    高敏
  • 依托单位: